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198Objective: The study objective was to investigate the effect of recombinant human hepatocyte growth factor
gene transfection via an endotracheal approach on hyperkinetic pulmonary artery hypertension rabbit models.
Methods: The rabbits with established pulmonary artery hypertension were separated into a gene transfection
group (rabbits treated with intratracheal instillation of human hepatocyte growth factor 23 109 plaque-forming
units coded by replication-defective recombinant adenovirus), an empty vector group, and a control group. Two
weeks after endotracheal gene transfection, immunohistochemistry examination and Western blot were used to
detect the protein expression of human hepatocyte growth factor. The hemodynamic data were measured, and
pulmonary angiography was performed to investigate the pulmonary collateral vessels. The vascular density in
lung also was analyzed.
Results: Two weeks after gene transfection, human hepatocyte growth factor was expressed in the gene trans-
fection group. The mean pulmonary artery pressure in the gene transfection group was lower than in the control
and empty vector groups (P<.05 for both). The arteriolar density in the lung tissues of the gene transfection
group was higher than in the other groups (P < .05), which was confirmed by immunohistochemistry,
double-labeling immunofluorescence, and pulmonary angiography.
Conclusions:Human hepatocyte growth factor was expressed in rabbit lung after gene transfection via an airway
approach. Recombinant human hepatocyte growth factor transfection ameliorates the pulmonary artery hyperten-
sion inducedby shuntflowbypromotingangiogenesis in lung tissues. (JThoracCardiovascSurg2013;146:198-205)Hyperkinetic pulmonary artery hypertension (PAH) is
a common and problematic complication of left-to-right
shunt congenital heart disease. It increases morbidity and
mortality, and seriously affects the prognosis of the patient.1
The current therapies of PAH mainly focus on the dilation
of pulmonary arteries, such as inhalation of nitric oxide
and administration of bosentan or prostacyclin. Although
palliation of PAHwas obtained from surgical manipulation2
and pharmacotherapies prolonged the survival of patients
with PAH, the long-term outcome was not favorable be-
cause of the obstructive remodeling of pulmonary arterioles
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The Journal of Thoracic and Cardiovascular SurgIn recent years, gene-based angiogenesis therapy has
gained interest in many research fields. Therapeutic angio-
genesis reduces vascular resistance and improves perfusion
of tissues.4,5 Hepatocyte growth factor (HGF) and its
receptor are widely distributed in the cardiovascular
system. This protein is characterized as a multifunctional
growth factor with mitogenic, antiapoptotic activities in
a variety of cells.6 As a highly efficient angiogenesis factor,
exogenous HGF has been used in the treatment of ischemic
diseases, such as limb ischemia or even ischemic heart dis-
ease,7,8 to promote neovascularization and improve
perfusion of ischemic tissues.
HGF is involved in lung regeneration and protection in re-
sponse to acute lung injury, and deficiency of endogenous
HGF is a feature of PAH pathogenesis.9 Its angiogenic effect
is more significant than that of vascular endothelial growth
factor and basic fibroblast growth factor. In addition, unlike
vascular endothelial growth factor and basic fibroblast
growth factor, HGF neither increases the permeability of
blood vessels nor promotes the overproliferation of vascular
smooth muscle cells (SMCs) to aggravate the original artery
stenosis.10,11 Thus, HGF is more suitable for the therapy of
PAH. Previous studies have reported the angiogenic effect of
recombinant human hepatocyte growth factor (rhHGF) gene
transferring into the lung via a catheter in rat models.9,12
However, there is no report on the application of rhHGF
coded by an adenovirus vector via the endotracheal
pathway under hyperkinetic pulmonary hypertensionery c July 2013
Abbreviations and Acronyms
Ad-hHGF ¼ adenovirus coding with human
hepatocyte growth factor
Ad-Null ¼ adenovirus without hepatocyte growth
factor gene
HGF ¼ hepatocyte growth factor
LV ¼ left ventricle
mPAP ¼ mean pulmonary artery pressure
PAH ¼ pulmonary artery hypertension
Pfu ¼ plaque-forming units
rhHGF ¼ recombinant human hepatocyte growth
factor
RV ¼ right ventricle
SMC ¼ smooth muscle cell
VEC ¼ vascular endothelial cell
VS ¼ ventricular septum
Wang et al Evolving Technology/Basic Scienceinduced by a left-to-right shunt. Therefore, we hypothesized
that exogenous HGF supplementation via a tracheal route
might ameliorate PAH induced by a systemic-pulmonary
shunt. In the current study, established PAH rabbit models
were administered rhHGF via an intratracheal route. The ef-
fects of rhHGF transfection on pulmonary arterial pressure
and the collateral vessel construction in lung tissues were in-
vestigated. Moreover, the relationship between pulmonary
angiogenesis and pulmonary artery pressure was analyzed
to explore the feasibility of exogenous HGF administration
in decreasing pulmonary artery pressure.E
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Animal Model Preparation
The study conformed to theGuide for theCare andUse ofLaboratoryAn-
imals of National Research Council of China. The experiment was approved
by theAnimalCareCommitteeof theXuzhouMedicalCollege ofChina. The
animals received humane care in compliancewith the Guide for the Care and
Use of Laboratory Animals of Jiangsu Province of China. One-month-old
New Zealand male rabbits (weighing 540 24 g) were supplied by the Lab-
oratory Animal Center of Xuzhou Medical College. A systemic-pulmonary
shunt was established with left common carotid artery and pulmonary trunk
anastomosis. The pulmonary hypertension model was established after
3 months, and the methods were described in our previous report.13
Preparation of Adenovirus Vectors
Recombinant adenovirus (replication-defective human serum adenovi-
rus type 5 with cytomegalovirus promoter) coding with human HGF
(Ad-hHGF) and adenovirus without HGF gene (Ad-Null) were constructed
by theAcademy ofMilitaryMedical Sciences and donated byAcademician
WuZuze. The recombinant adenoviruswas purified by cesium chloride gra-
dient centrifugation and desalted using Dialysis Cassettes (Slide-A-Lyzer
10k; Pierce, Rockford, Ill). The final plaque-forming units (Pfu) of virus
were determined by titration on 293 cells under an agar overlay (Low Gel-
ling Temperature; Sigma-Aldrich, St Louis, Mo). The virus was stored at
80C and protected from light until use. The purity of Ad-hHGF and
Ad-Null was 1.32 and 1.31, respectively. The efficacy and safety of Ad-
hHGF have been proven by Ha and colleagues.14The Journal of Thoracic and CaExperimental Groups
The rabbits with established PAH (n¼ 36) were randomly separated into
3 groups: control group (C group, intratracheal instillation of phosphate-
buffered saline, n ¼ 12), empty virus control group (E group, intratracheal
instillation of Ad-Null 23 109 Pfu, n¼ 12), and Ad-hHGF treatment group
(H group, intratracheal instillation of Ad-hHGF 23 109 Pfu as previously
described,15,16 n ¼ 12). Briefly, after sterilization of the skin, the trachea
was approached via a thyrocricoid puncture, and 200 mL of vehicle
containing the Ad-hHGF 2 3 109 Pfu or equivalent Ad-Null or
phosphate-buffered saline was instilled into the trachea. Immediately be-
fore instillation, circumferential compression of the thorax was performed
to achieve a forced exhalation. After endotracheal instillation followed by
20 mL of air, compression was released. This caused a forceful inspiration
that facilitated the adenoviral dispersion to the distal air spaces. The infec-
tive titer had been determined through preliminary experiments, in which
the group with 2 3 109 Pfu showed the largest improvement in the PAH
models and with less mortality than in the groups with other different titers.
Measurement of Hemodynamic Parameters
Two weeks after Ad-hHGF transfection, animals were anesthetized
with an intramuscular injection of ketamine (2 mg/kg) and midazolam
(1mg/kg), followed by an intravenous bolus of ketamine (1mg/kg) through
the ear vein. The animals were intubated and supported with a ventilator. A
stable anesthesia was maintained with continuous intravenous infusion of
fentanyl (30 mg $ kg1 $ h1) and midazolam (2 mg $ kg1 $ h1). A right
thoracotomy was performed through the fourth intercostal space. A
purse-string suture was made on the ascending aorta and the pulmonary
trunk with 7-0 Prolene (Ethicon Inc, Somerville, NJ). A piezometric cath-
eter (4F) was inserted, and the hemodynamic parameters were monitored
simultaneously with the MacLab/8s multifunction physiologic instrument
(M8680, ADInstruments Pty Ltd, Bella Vista, Australia). Hemodynamic
parameters were recorded, including systolic pulmonary artery pressure,
diastolic pulmonary artery pressure, mean pulmonary artery pressure
(mPAP), and mean systemic arterial pressure.
Pulmonary Artery Angiography
After hemodynamic parameters were measured, pulmonary angiogra-
phy was performed with digital subtraction angiography (Innova 4100,
GEHealthcare,Waukesha,Wis).Via a piezometric catheter, 5mLofmeglu-
mine was injected into the pulmonary artery, which was used for pressure
measurement, and the images were recorded. The morphology, distribution
of pulmonary artery, and construction of collateral circulation were investi-
gated. The meglumine filling time also was recorded and analyzed.
Preparation of the Tissues
The animals were euthanizedwith an overdose of 3% pentobarbital (90-
120mg/kg) via an intravenous infusion after imaging the pulmonary artery.
Lung samples (13 13 1 cm) were cut from the apex of the superior lobe of
the right lung forWestern blot analysis. The left lung inferior lobewas fixed
by 10% formalin and routinely processed into paraffin sections of 5 mm in
depth.
The great vessels were separated from the heart, and the residual blood
was blotted. The heart was separated into the right ventricle (RV) and left
ventricle (LV) plus ventricular septum (LVþVS) according to the methods
previously described.17 The RVweight index (LV/LVþVS) was calculated
to evaluate the hypertrophy of RV.13,18
Immunohistochemistry Examination
Ten slices were randomly selected in each model to detect the target
proteins. After the slices were deparaffinaged with dimethylbenzene,
they were washed twice and then heat processed (92C-98C) for 15 min-
utes to recover the antigens. The slices were blocked with goat serum and
incubated with mouse antihuman HGF monoclonal antibody (1:100, Santardiovascular Surgery c Volume 146, Number 1 199
TABLE 1. Hemodynamic measurement and weight index of right
ventricle in experimental rabbits
C group
(n ¼ 12)
E group
(n ¼ 12)
H group
(n ¼ 12)
sPAP (mm Hg) 33.65  4.12 29.99  5.22 16.61  3.40*,y
dPAP (mm Hg) 15.28  3.31 17.04  2.93 8.45  2.12*,y
mPAP (mm Hg) 21.14  2.61 22.81  3.81 12.47  3.49*,y
mSAP (mm Hg) 71.22  13.90 69.39  16.23 73.17  15.16
RV/BW (g/kg) 0.92  0.21 0.89  0.32 0.52  0.42*,y
LV/BW (g/kg) 2.61  0.82 2.77  0.39 2.81  0.24
RV/(LVþVS) 0.45  0.03 0.47  0.07 0.25  0.09*,y
Heart rate (beats/min) 247  51 261  49 274  38
sPAP, Systolic pulmonary artery pressure; dPAP, diastolic pulmonary artery pressure;
mPAP, mean pulmonary artery pressure; mSAP, mean systemic arterial pressure;
RV, right ventricle; BW, body weight; LV, left ventricle; VS, ventricular septum.
*P<.05 versus C group. yP<.05 versus E group.
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SCruz Biotechnology Inc, Santa Cruz, Calif) or rat anti-VIII factor (1:150,
Santa Cruz Biotechnology Inc) at 4C overnight. Biotinylated second anti-
body was added for 30 minutes at 37C. Then the slides were incubated
with avidin-biotin complex at 37C for 30 minutes. DAB kit (ZhongShan
Golden Bridge Biological Technology, Bejing, China) was used for chro-
mogenic reaction, and the slices were counterstained with hematoxylin.
Control sections were incubated with noninmmune mouse or rat
immunoglobulin-G at a concentration of 1:500. The pathologist was
blinded to the experiments. The hHGF levels were quantified by the Image
Pro Plus 6.0 system (Media Cybernetics Inc, Rockville, Md). The pulmo-
nary arterial density was determined as the average number of the VIII fac-
tor–positive stained arteries along terminal bronchiole per millimeter
squared as previously described.19
Double-Labeling Immunofluorescence
Paraffin sections of lung tissues were treated with hydrogen peroxide
and blocked with goat serum. After incubation with the mixed primary an-
tibody (mixture of mouse anti-a smooth muscle actin [ZhongShan Golden
Bridge Biological Technology] and rat anti-VIII factor), rhodamine-
labeled goat antimouse secondary antibody and fluorescein isothiocya-
nate–labeled goat antirat secondary antibody were used to display the
SMCs and vascular endothelial cells (VECs) in the lung vessels, respec-
tively. All manipulations were kept away from light. Four fields of vision
were selected randomly in each slice and photographed under high-
power microscope. The positive signals and the intensity of the fluores-
cence were analyzed by the Image Pro Plus 6.0 system.
Western Blot
Protein was drawn from 20 mg of lung tissues, and protein concentra-
tions were determined by the Bio-Rad protein assay instrument (Bio-Rad
Laboratories Inc, Hercules, Calif). Equal amounts of protein were
dissolved in sodium dodecyl sulfate polyacrylamide gel electrophoresis
sample buffer, separated in sodium dodecyl sulfate polyacrylamide gel
electrophoresis, and transferred onto polyvinylidene fluoride membrane.
The membranes were incubated with the primary antibodies (mouse anti-
hHGF) overnight at 4C and incubated with secondary antibodies conju-
gated to horseradish peroxidase for 1 hour at room temperature with
continuous shaking. Protein blots were detected using an enhanced chem-
iluminescence kit (Millipore Corp, Billerica, Mass) and exposed to x-ray
film. The recognized bands were quantified by FluorChem 9900 (Alpha In-
notech, Santa Clara, Calif), and glyceraldehyde phosphate dehydrogenase
was used as an internal reference.
Statistical Analysis
Data are shown as mean  standard deviation. The Statistical Package
for the Social Sciences version 13.0 (SPSS Inc, Chicago, Ill) for Windows
was used for all statistical analysis. One-way analysis of variance with
a post hoc test of the least significant difference was used for statistical
analysis.
RESULTS
Hemodynamic Changes
No animals died or experienced respiratory and other
complications after the treatments. Two weeks after gene
transfection, the mPAP (16.61  3.40 mm Hg) and the
weight index of the RV (0.25  0.09) in the H group were
significantly lower than in the C group (33.65  4.12 mm
Hg and 0.45  0.03, respectively) or E group
(29.99  5.22 mm Hg and 0.47  0.07, respectively,
Table 1). There were no significant differences in the
mean systemic arterial pressure among the 3 groups.200 The Journal of Thoracic and Cardiovascular SurgFurthermore, the difference in mPAP between the C and
E groups was not significant. After the gene transfection,
there were no differences in heart rate among the groups.Expression of Human Hepatocyte Growth Factor
Protein in Lung Tissues
Two weeks after the treatment, immunohistochemistry
examination showed no hHGF-positive signals in the lung
tissues of the C and E groups. In the H group, diffuse immu-
nostaining for hHGF was observed in the cytoplasm of
VECs and alveolar epithelial cells. With the intratracheal
approach, the hHGF expression in the tracheobronchial
tree also was detected. Immunostaining examination
showed a relatively high expression of hHGF in the bron-
chial ciliated cells and basal epithelial cells (Figure 1, A
and B). To confirm that the expressed protein in lung tissues
was hHGF, Western blot analysis was performed. Likewise,
in addition to the glyceraldehyde phosphate dehydrogenase,
the recognized band representing hHGF protein was de-
tected in the H group. In contrast, hHGF was undetectable
in the C and E groups (Figure 1, C and D). All these results
showed the expression of rhHGF protein in the lung tissues
after transfection, which indicated that the endotracheal
approach was an efficient pathway for gene transfection
of the lung.Impact of Adenovirus Coding With Human
Hepatocyte Growth Factor Transfection on Vessel
Density in Lung
To evaluate the angiogenesis in lung after gene transfec-
tion, VIII factor, a specific marker for VECs, was examined
in the lung tissues. Twoweeks after rhHGF transfection, im-
munocytochemistry stain of VIII factor showed that the mi-
crovascular density in the lung tissues of the H group was
19.7  2.8/mm2, which was significantly higher than
in the C group (13.2  3.2/mm2, P< .05) and E group
(14.8  2.7/mm2, P<.05, Figure 2). These results impliedery c July 2013
FIGURE 1. A, Immunohistochemistry examination of hHGF in lung tissues (n ¼ 120 slices per group). A-a, C group. A-b, E group. A-c, H group. A-d,
Magnification of A-c. A-e, hHGF expression in the bronchial epithelium. In contrast to the C and E groups, positive signals were observed in the cytoplasm
of VECs and epithelial cells in lung tissues of the H group. Bar ¼ 100 mm. B, Semiquantitative analysis of the hHGF immunohistochemistry examination.
a, C group. b, E group. c, H group. *P<.05 versus C group. #P<.05 versus E group. C, Western blot showed that no specific band in the C and E groups
(n¼ 12 per group) and the band in the H group (n¼ 12) were proved to be the hHGF after gene transfection. D, Relative intensity of hHGF in the 3 groups.
a, C group. b, E group. c, H group.*P<.05 versus C group. #P<.05 versus E group. GAPDH, Glyceraldehyde phosphate dehydrogenase; hHGF, human
hepatocyte growth factor.
Wang et al Evolving Technology/Basic Sciencethat the arteriolar density was increased in lung tissues after
hHGF transfection in rabbits with PAH.
There were 3 types of acinar artery in the lung: muscular,
partial muscular, and nonmuscular. The nonmuscular-type
and partial muscular–type vessels were the main functional
vessels; the latter especially plays an important role in the
perfusion of lung tissues. The promotion of the partial mus-
cular artery also was assayed using double-labeling immu-
nofluorescence histochemistry. VECs were labeled with
fluorescein isothiocyanate (VIII factor staining), and
SMCs were labeled with rhodamine (a-smooth muscle
actin antibody). Immunofluorescence analysis suggested
that the density of partial muscular arteries in the H group
was higher than in the C and E groups (17.3  3.5/mm2
vs 9.5  3.2/mm2, P < .05; and 17.3  3.5/mm2 vs
7.4  2.7/mm2, P<.05, respectively) (Figure 3). The in-
crease in nonmuscular (VIII factor stain) and partial muscu-
lar arteries (double-labeling immunofluorescence) ensured
efficient gas exchange and perfusion in the H group. These
results showed that rhHGF transfection promoted func-
tional angiogenesis in the lung tissue of PAH models.E
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SMorphology and Distribution of Pulmonary
Arterioles
Tomeasure lung blood perfusion, pulmonary artery angi-
ography was performed. In the C and E groups, the expan-
sion of pulmonary trunk, sudden attenuation, or terminationThe Journal of Thoracic and Caof pulmonary artery branches, which was called ‘‘residual
root-like’’ changes, and decrease of remote branches of pul-
monary artery were observed in the pulmonary artery angi-
ography (Figure 4). In the H group, pulmonary hypertension
images also were observed, but the changes in the pulmo-
nary trunk were slight and the number of remote branches
of the pulmonary artery obviously increased with the
distribution in a network style. Prolonged contrast medium
filling time in the pulmonary artery (including the termina-
tion branches) was detected in the C group (2376 748 ms,
n ¼ 12) and E group (2197  581 ms, n ¼ 12). The meglu-
mine filling time in the H group (n¼ 12) was shorter than in
the C and E groups (1579  542 ms vs 2376  748 ms,
P<.05 and 1579  542 ms vs 2197  581 ms, P<.05,
respectively).DISCUSSION
The current study demonstrated that (1) the intratracheal
transfection of the rhHGF induced the expression of hHGF
in lung tissues of rabbits with PAH; (2) the transfection of
rhHGF ameliorated pulmonary arterial pressure in animals
with PAH induced by a shunt flow; and (3) the decrease in
pulmonary arterial pressure and improvement in blood per-
fusion after rhHGF transfection may be due to the arteriolar
angiogenesis in the lung.
A number of different viral and nonviral vector systems
are in use to transfer genes to lung tissue. Each vector hasrdiovascular Surgery c Volume 146, Number 1 201
FIGURE 2. Immunohistochemistry examination for anti-VIII factor stain (n ¼ 120 slices per group). A, C group. B, E group. C, H group. Bar ¼ 100 mm.
*P<.05 versus C group. #P<.05 versus E group.
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The replication-incompetent recombinant adenovirus was
used in the current study because of its high-efficiency
transduction in a wide variety of target cells and high ex-
pression of the delivery transgene. Furthermore, adenovirus
is stable in vivo, permitting direct delivery of the gene to the
lung parenchyma.20 According to the characteristics of ad-
enovirus and the respiratory system, Ad-hHGF could be de-
livered through the endotracheal pathway but not via an
invasive method, such as catheter insertion.9,12 Local and
systemic inflammatory responses were the main
disadvantage of adenovirus-mediated gene transfection.
The preliminary study21 showed that unlike the intravenous
method, the intratracheal pathway for gene transfer to lung
confined the transient inflammation response in the respira-
tory tract rather than in the system. Moreover, with the use202 The Journal of Thoracic and Cardiovascular Surgof green fluorescent protein as a report gene, our early study
showed that there are few signals of green fluorescent
protein in the heart and liver tissues via an intratracheal
approach.21 After gene transfection, no symptoms of respi-
ratory or other complications were detected in the animals.
Systemic arterial pressure and heart rate were not influ-
enced in the rabbits in the E and H groups. Furthermore,
hHGF is highly expressed in bronchial epithelium, alveolar
epithelium, and pulmonary VECs. Immunoblotting also
confirmed that the expressed protein was hHGF. These
results implied that intratracheal transfer of Ad-Null or
Ad-hHGF was safe and targeted the respiratory system.
Therefore, gene transfer to the pulmonary vascular bed
via an intratracheal approach was an effective method for
administering a viral vector in the treatment of pulmonary
disease. In addition to the high efficiency and clearery c July 2013
FIGURE 3. VIII factor antibody was labeled with fluorescein isothiocyanate (green), and a-smooth muscle actin antibody was labeled with rhodamine
(red). Arrows indicate the partial muscular arteries. A1-A3, C group. B1-B3, E group. C1-C3, H group. Bar ¼ 100 mm. The partial muscular vessel density
was analyzed (n ¼ 120 per group). A, C group. B, E group. C, H group. *P<.05 versus C group. #P<.05 versus E group. a-SMA, a-smooth muscle actin.
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Stargeting, gene transfer to lung with an intratracheal ap-
proach avoided the blood dilution and severe systemic in-
flammation caused by the vehicle.
In the vascular remodeling caused by PAH, pulmonary
intra-acinar arteries are the key blood vessels for hemody-
namic regulation. With transformation of the nonmuscular
and partialmuscular types into themuscular type, luminal ste-
nosis and occlusion are the pathologic basis of PAH.22 The
rhHGF transfection in the current study promoted angiogen-
esis in the lung tissues of PAHmodels, which was confirmed
by immunohistochemistry. The partial muscular–type artery
was the main vessel for controlling perfusion of the lung.The Journal of Thoracic and CaImmunofluorescence examination showed that the partial
muscular–type arteries were significantly increased after
hHGF transfection. Therapeutic angiogenesis promoted the
collateral circulation and thus reduced the vascular resistance
and improved the perfusionof the organ.Thismight have con-
tributed to the decrease in pulmonary arterial pressure in the
H group. Of note, although the hHGF transfection promoted
the generation of partial muscular type arteries in the lung, it
did not aggravate the original proliferation of SMCs. This
phenomenon might be due to the antifibrotic character of
HGF, which had been thoroughly proved.11,23 HGF
promoted angiogenesis after transfection but also inhibitedrdiovascular Surgery c Volume 146, Number 1 203
FIGURE 4. Pulmonary artery angiography under digital subtraction angiography. A, C group. B, E group. C, H group. The contrast filling time was cal-
culated in the angiography (n ¼ 12 per group). *P<.05 versus C group. #P<.05 versus E group.
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antifibrotic mechanisms, such as attenuation of collagen
accumulation.11 The pulmonary angiography results corre-
lated well with the results of immunocytochemistry and im-
munofluorescence stain for vascular density. Pulmonary
angiography showed that themeglumine filling timewas pro-
longed in theC andE groups, whichmayhave been caused by
the partial occlusion of the arterioles in the rabbits with PAH.
In the H group, the enlargement of the pulmonary vascular
bed decreased the resistance of the contrastmediumperfusion
to a certain degree. Thus, we speculated that Ad-hHGF trans-
fection effectively reduced the pulmonary artery pressure via
the angiogenesis in the lung. This result was partially con-
firmed in previous studies.12,16
Because of the heterogeneity of the vehicle and
exogenous gene, the innate immunoreaction was activated,
which resulted in the production of neutralizing antibodies
by the host, preventing the productive readministration. A
previous study by Wang and colleagues16 indicated that204 The Journal of Thoracic and Cardiovascular Surgthe repeated application had an inefficient gene delivery
and that the hHGF expression was gradually attenuated
and eliminated after 4 weeks in the adenovirus-mediated
gene transfer. It was speculated that after the first transfec-
tion, a specific antibody had been produced to avoid the side
effects caused by the prolonged exogenous gene expression.
Therefore, short-term and stepwise expression of the
adenovirus-mediated hHGF gene guaranteed the safety of
the treatment, especially in PAH. Because the recombinant
genes that can independently express a therapeutic RNA or
protein are extraordinarily large and polar molecules
(10,000 times larger than traditional pharmaceutical
agents24), a single transfection achieved a satisfying result.
However, the long-term therapeutic effect of hHGF and the
survival analysis in PAH deserve further investigation.
Study Limitations
A limitation of this study was the absence of data on
the V/Q ratio or the blood gas analysis after the geneery c July 2013
Wang et al Evolving Technology/Basic Sciencetransfection. In addition, the measurement of right ventricu-
lar function should be performed to better delineate the PAH
improvement. The changes of the relative factors that were
important in the development of PAH (eg, endothelial nitric
oxide synthase) are being investigated to explore the underly-
ing mechanisms induced by the hHGF gene transfection.
CONCLUSIONS
Collectively, rhHGF transfection via an endotracheal ap-
proach in the PAH rabbit models induced by shunt flow
decreases pulmonary artery pressure by promoting angio-
genesis in the lung. The current study may provide new
ideas for the therapy of PAH induced by shunt flow, which
is significant for advanced congenital cardiac disease.
The authors thank academician Wu Zuze for the donation of re-
combinant adenovirus vector and the technologic guidance.
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